Although ERα+ breast cancers harbor lower mutation load than TNBCs [140], heterogeneity due to acquired plasticity of cancer cells remains a major mechanism of resistance to targeted therapies and a better understanding of this plasticity will aid in the development of new therapies. The gene discussed is ESR1; the disease is breast cancer.